Stability of aclidinium bromide inhalation powder (200 (mu)g per dose) delivered from the Genuair(registered trademark) inhaler

  • K. B
  • S. F
  • B. F
  • 5


    Mendeley users who have this article in their library.
  • N/A


    Citations of this article.


Rationale: Aclidinium bromide is currently in Phase III development for the treatment of chronic obstructive pulmonary disease. Drug stability and inhaler performance can be affected by environmental conditions. This study evaluated the effect of temperature and humidity on the stability of the aclidinium 200 (mu)g formulation delivered from the Genuair(registered trademark) inhalernull. Methods: Two laboratory scale (LS) batches and 3 pilot scale (PS) batches of aclidinium were stored (for up to 3 years and 2 years, respectively) and periodically analyzed for purity and stability. Storage conditions were for climatic zones II (25(degrees)C/60% relative humidity [RH]) and IV (30(degrees)C/65% RH), as well as accelerated conditions of 25(degrees)C/75% RH (ACI) and 40(degrees)C/75% RH (ACII). Results: No change in delivered dose and no significant change in particle size were observed with different storage conditions. The initial impurity profile was very low (total impurity

Author-supplied keywords

  • aclidinium bromide
  • chronic obstructive lung disease
  • drug stability
  • dry powder
  • humidity
  • inhalation
  • inhaler
  • laboratory
  • particle size
  • powder
  • society
  • storage
  • temperature

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document


  • Block K.

  • Folger S.

  • Fyrnys B.

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free